“High price tags for new medicines are about to come under renewed pressure”
The Economist December 10th 2016
“The industry says its products save money for the health-care system, and that profits are the source of investment for creating the drugs of the future. Both points are sometime true. But with many pharma firms buying in drugs, rather than developing them in-house, there is a strong case that drug prices currently have more to do with the cost of dealmaking than the cost of innovation”
